jetcityimage Bernstein started coverage of Eli Lilly ( NYSE: LLY ), Gilead Sciences ( NASDAQ: GILD ) and Amgen ( NASDAQ: AMGN ) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen were based on upside expectations for key assets to generate revenue growth between.